{
    "nct_id": "NCT02985957",
    "official_title": "A Phase 2 Trial of Nivolumab Plus Ipilimumab, Ipilimumab Alone, or Cabazitaxel in Men With Metastatic Castration-Resistant Prostate Cancer",
    "inclusion_criteria": "* Eastern Cooperative Oncology Group (ECOG) performance status 0-1\n* Current evidence of metastatic disease documented by either bone lesions on radionuclide bone scan and/or soft tissue lesions on computerized tomography/magnetic resonance imaging (CT/MRI).\n* Ongoing androgen deprivation therapy (ADT) with a Gonadotropin-releasing hormone (GnRH) analogue or a surgical/medical castration with testosterone level of â‰¤1.73nmol/L (50ng/dL)\n\nFor crossover phase for participants originally randomized to Arm D3 or Arm D4 only:\n\n* Previously randomized to Arm D3 or D4; had histologic confirmation of adenocarcinoma of the prostate and evidence of Stage IV disease (as defined by American Joint Committee of Cancer criteria (AJCC criteria) prior to randomization\nHealthy volunteers allowed\nMust be MALE\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Presence of visceral metastases in the liver\n* Active brain metastases or leptomeningeal metastases\n* Active, known, or suspected autoimmune disease or infection\n* Prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, or anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways\n\nFor crossover phase for participants originally randomized to Arm D3 or Arm D4 only:\n\n* Prior radiation therapy within 14 days prior to first dose of nivolumab combined with ipilimumab\n* Have received systemic anti-cancer therapy after the last dose of study treatment (ipilimumab or cabazitaxel)\n\nOther protocol-defined inclusion/exclusion criteria apply",
    "miscellaneous_criteria": ""
}